Joanne Wuensch
Stock Analyst at Citigroup
(4.43)
# 243
Out of 4,826 analysts
373
Total ratings
62.55%
Success rate
11.65%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb | Maintains: Neutral | $14 → $13 | $11.33 | +14.74% | 5 | May 1, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Buy | $105 → $86 | $69.37 | +23.97% | 4 | Apr 30, 2025 | |
| COO The Cooper Companies | Maintains: Buy | $115 → $110 | $81.61 | +34.80% | 20 | Mar 7, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $135 → $160 | $132.60 | +20.66% | 20 | Mar 4, 2025 | |
| DXCM DexCom | Maintains: Buy | $101 → $104 | $80.25 | +29.60% | 13 | Mar 4, 2025 | |
| SGHT Sight Sciences | Maintains: Neutral | $4.6 → $3 | $2.93 | +2.39% | 10 | Mar 4, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Neutral | $35 → $24 | $21.33 | +12.52% | 14 | Mar 4, 2025 | |
| MDT Medtronic | Upgrades: Buy | $92 → $107 | $83.35 | +28.37% | 19 | Mar 4, 2025 | |
| SYK Stryker | Reinstates: Buy | $450 | $381.56 | +17.94% | 13 | Feb 26, 2025 | |
| PODD Insulet | Maintains: Buy | $310 → $355 | $258.83 | +37.16% | 14 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $122 | $104.24 | +17.04% | 34 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $640 → $711 | $531.82 | +33.69% | 16 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $200 → $245 | $294.17 | -16.71% | 24 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $185 → $175 | $155.00 | +12.90% | 12 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $145 | $116.48 | +24.48% | 4 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $83 | $75.20 | +10.37% | 19 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $37 → $35 | $30.43 | +15.02% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $7.5 | $3.60 | +108.33% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $132 → $162 | $86.86 | +86.51% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $22 | $13.28 | +65.66% | 14 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $33.51 | +49.21% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $110 | $135.65 | -18.91% | 17 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $85 | $62.49 | +36.02% | 7 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $134 → $120 | $90.48 | +32.63% | 22 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $167.00 | +49.70% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $97.38 | -29.14% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $240.66 | -47.23% | 6 | Dec 10, 2018 |
Bausch + Lomb
May 1, 2025
Maintains: Neutral
Price Target: $14 → $13
Current: $11.33
Upside: +14.74%
GE HealthCare Technologies
Apr 30, 2025
Maintains: Buy
Price Target: $105 → $86
Current: $69.37
Upside: +23.97%
The Cooper Companies
Mar 7, 2025
Maintains: Buy
Price Target: $115 → $110
Current: $81.61
Upside: +34.80%
Abbott Laboratories
Mar 4, 2025
Maintains: Buy
Price Target: $135 → $160
Current: $132.60
Upside: +20.66%
DexCom
Mar 4, 2025
Maintains: Buy
Price Target: $101 → $104
Current: $80.25
Upside: +29.60%
Sight Sciences
Mar 4, 2025
Maintains: Neutral
Price Target: $4.6 → $3
Current: $2.93
Upside: +2.39%
Tandem Diabetes Care
Mar 4, 2025
Downgrades: Neutral
Price Target: $35 → $24
Current: $21.33
Upside: +12.52%
Medtronic
Mar 4, 2025
Upgrades: Buy
Price Target: $92 → $107
Current: $83.35
Upside: +28.37%
Stryker
Feb 26, 2025
Reinstates: Buy
Price Target: $450
Current: $381.56
Upside: +17.94%
Insulet
Feb 21, 2025
Maintains: Buy
Price Target: $310 → $355
Current: $258.83
Upside: +37.16%
Feb 6, 2025
Maintains: Buy
Price Target: $107 → $122
Current: $104.24
Upside: +17.04%
Jan 24, 2025
Maintains: Buy
Price Target: $640 → $711
Current: $531.82
Upside: +33.69%
Dec 11, 2024
Maintains: Neutral
Price Target: $200 → $245
Current: $294.17
Upside: -16.71%
Dec 11, 2024
Maintains: Buy
Price Target: $185 → $175
Current: $155.00
Upside: +12.90%
Dec 11, 2024
Maintains: Neutral
Price Target: $130 → $145
Current: $116.48
Upside: +24.48%
Dec 11, 2024
Maintains: Buy
Price Target: $81 → $83
Current: $75.20
Upside: +10.37%
Dec 11, 2024
Maintains: Neutral
Price Target: $37 → $35
Current: $30.43
Upside: +15.02%
Dec 11, 2024
Downgrades: Neutral
Price Target: $17 → $7.5
Current: $3.60
Upside: +108.33%
Dec 11, 2024
Upgrades: Buy
Price Target: $132 → $162
Current: $86.86
Upside: +86.51%
Nov 5, 2024
Maintains: Sell
Price Target: $16 → $22
Current: $13.28
Upside: +65.66%
Oct 1, 2024
Maintains: Neutral
Price Target: $45 → $50
Current: $33.51
Upside: +49.21%
Aug 22, 2024
Maintains: Buy
Price Target: $135 → $110
Current: $135.65
Upside: -18.91%
Aug 22, 2024
Maintains: Neutral
Price Target: $94 → $85
Current: $62.49
Upside: +36.02%
Jul 10, 2024
Maintains: Neutral
Price Target: $134 → $120
Current: $90.48
Upside: +32.63%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $167.00
Upside: +49.70%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $97.38
Upside: -29.14%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $240.66
Upside: -47.23%